HLA-E and myeloid sarcoma: If confirmed, HLA‐E*01:01 screening, along with other MS‐related alleles, could improve MS risk assessment and become a key tool for targeted monitoring and early detection strategies in EBV‐exposed individuals, particularly those with a history of IM diagnosis, and who could benefit from closer monitoring for early intervention.